Abstract
Anti-idiotypic antibodies (Ab2) binding to the antigen-combining site of antitumor antibodies (Ab1) can induce anti-anti-idiotypic antibodies (Ab3) that specifically bind to the tumor antigen recognized by Ab1. Furthermore, Ab2, mimicking tumor antigens, have been shown to induce anti-anti-idiotypic proliferative T lymphocytes of the helper and suppressor type, as well as cytotoxic lymphocytes. The immunomodulatory activities of Ab2 have been demonstrated both in animals and in patients. The demonstration of tumor growth inhibition by anti-idiotypes in preclinical and phase I clinical studies emphasizes that randomized control trials should be performed to demonstrate clinical efficacy of Ab2 vaccines.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 25 July 1996 / Accepted: 22 August 1996
Rights and permissions
About this article
Cite this article
Herlyn, D., Somasundaram, R., Li, W. et al. Anti-idiotype cancer vaccines: past and future. Cancer Immunol Immunother 43, 65–76 (1996). https://doi.org/10.1007/s002620050305
Issue Date:
DOI: https://doi.org/10.1007/s002620050305